Suppr超能文献

单次排卵中期剂量的左炔诺孕酮类似于紧急避孕药,不会改变 L-选择素配体或子宫内膜容受性的分子标志物的表达。

A single midcycle dose of levonorgestrel similar to emergency contraceptive does not alter the expression of the L-selectin ligand or molecular markers of endometrial receptivity.

机构信息

Instituto de Investigaciones Materno Infantil, Universidad de Chile, Santiago de Chile, Chile.

出版信息

Fertil Steril. 2010 Oct;94(5):1589-94. doi: 10.1016/j.fertnstert.2009.09.013. Epub 2009 Nov 11.

Abstract

OBJECTIVE

To examine the effects of a single-dose of 1.5 mg of levonorgestrel (commonly used as emergency contraceptive) on endometrial receptivity biomarkers through the oral or vaginal route.

DESIGN

Prospective randomized single-blinded trial.

SETTING

Affiliated Hospital and University Research Center.

PATIENT(S): Fertile normal women previously sterilized by tubal ligation.

INTERVENTION(S): Levonorgestrel (1.5 mg) was administered on the day of LH surge either orally (n = 14) or vaginally (n = 13).

MAIN OUTCOME MEASURE(S): Molecular assessment of endometrial progesterone receptors, L-selectin ligand, glicodelin-A and αvβ3 integrin by Immunohistochemistry and reverse transcriptase-polymerase chain reaction.

RESULT(S): Plasma progesterone concentration and endometrial dating were not different. The pattern of progesterone receptors and glycodelin-A expression was not affected during the early and midsecretory phase. Some endometrial biopsies from the group in which levonorgetrel was orally administered showed areas of glandular atrophy and stromal decidualization. However, the expression of the progesterone receptor, L-selectin ligand, αvβ3 integrin, and glycodelin-A were not different between the groups.

CONCLUSION(S): Levonorgestrel, given as emergency contraceptive on the day of LH surge, does not disrupt either ovulation or progesterone production by the corpus luteum. The contraceptive mechanism of levonorgestrel at the time of LH surge does not include changes in the progesterone receptors or the endometrial receptivity biomarkers.

摘要

目的

通过口服或阴道途径,研究单剂量 1.5 毫克左炔诺孕酮(通常用作紧急避孕药)对子宫内膜容受性生物标志物的影响。

设计

前瞻性随机单盲试验。

地点

附属医院和大学研究中心。

患者

以前通过输卵管结扎绝育的有生育能力的正常女性。

干预措施

在 LH 激增日口服(n = 14)或阴道内(n = 13)给予左炔诺孕酮(1.5 毫克)。

主要观察指标

通过免疫组织化学和逆转录聚合酶链反应对子宫内膜孕激素受体、L-选择素配体、糖蛋白 A 和αvβ3 整合素进行分子评估。

结果

血浆孕酮浓度和子宫内膜分期没有差异。孕激素受体和糖蛋白 A 表达模式在早、中分泌期不受影响。一些在口服左炔诺孕酮的组中进行的子宫内膜活检显示出腺体萎缩和间质蜕膜化的区域。然而,孕激素受体、L-选择素配体、αvβ3 整合素和糖蛋白 A 的表达在两组之间没有差异。

结论

在 LH 激增日给予紧急避孕药左炔诺孕酮并不会干扰排卵或黄体产生的孕激素。左炔诺孕酮在 LH 激增时的避孕机制不包括孕激素受体或子宫内膜容受性生物标志物的变化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验